Displaying 1 - 20 of 4921
Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill Federal Trade Commission - In the Matter of Ferrellgas Partners, L.P., et al.
Federal Trade Commission Act
Clayton Act
Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.
Edwards Lifesciences Corporation and JenaValve Technology, Inc., FTC v.
FTC Announces 2026 Jurisdictional Threshold Updates for Interlocking Directorates
FTC Announces 2026 Update of Jurisdictional and Fee Thresholds for Premerger Notification Filings
Facebook, Inc., FTC v. (FTC v. Meta Platforms, Inc.)
The Federal Trade Commission has sued Facebook, alleging that the company is illegally maintaining its personal social networking monopoly through a years-long course of anticompetitive conduct. The complaint alleges that Facebook has engaged in a systematic strategy—including its 2012 acquisition of up-and-coming rival Instagram, its 2014 acquisition of the mobile messaging app WhatsApp, and the imposition of anticompetitive conditions on software developers—to eliminate threats to its monopoly. The Commission vote to authorize staff to file for a permanent injunction and other equitable relief in the U.S. District Court for the District of Columbia was 3-2. Commissioners Noah Joshua Phillips and Christine S. Wilson voted no.
Statement on FTC Victory Halting Anticompetitive Medical Device Deal
Edwards Lifesciences Corp. and JenaValve Technology, Inc., In the Matter of
The Federal Trade Commission issued an administrative complaint to block medical device supplier Edwards Lifesciences Corp.’s (Edwards) proposed acquisition of JenaValve Technology, Inc. (JenaValve) due to concerns that the acquisition would limit patient access to lifesaving medical devices used to treat a potentially fatal heart condition. On January 9, 2026, after a six-day trial, the U.S. District Court for the District of Columbia granted the FTC’s request for a preliminary injunction to temporarily prevent Edwards from acquiring JenaValve.